| 释义 |
- Investors
- Notes
- External links
{{Infobox company
| name = Intarcia Therapeutics, Inc.
| logo = Intarcia Therapeutics logo.png
| type = Private
| foundation = Hayward, California, United States ({{Start date|1995}})
| location_city = Boston, MA
| location_country = United States
| key_people = {{ubl|Kurt C. Graves (Chairman, President and CEO)}}
| industry = pharmaceutical industry
| products = Medici Drug Delivery System
| homepage = {{URL|http://intarcia.com/}}
| footnotes =
}}Intarcia Therapeutics is an American biopharmaceutical company based in Boston, MA and incorporated under the laws of Delaware.[[2] It was founded in 1995 under the name "BioMedicines" and changed to its present name in 2004.][ In 2013, Intarcia relocated its headquarters to Boston, keeping its manufacturing facility in Hayward, CA. In addition to Boston and Hayward, Intarcia also has a location in Research Triangle Park, North Carolina, where it discovers and develops peptides for its drug delivery system.[1]]In 2005, the executive leadership of Intarcia was largely vested in two people, Karling Leung and James Ahlers, President/CEO/Director and Vice President/CFO/Finance & Operations Officer, respectively.[5] By 2012, Kurt Graves had replaced Karling Leung as President and CEO.[6] Kurt Graves has been with Intarcia since August 2010, first serving as Executive Chairman before becoming President and CEO in April 2012.[2] {{As of|2016}}, Intarcia is engaged in development of a "potential once-a-year type 2 diabetes treatment". Referred to as ITCA 650, the therapeutic consists of exenatide delivered via its Medici Drug Delivery System,[8] "a drug delivery platform that stabilizes and delivers therapeutic proteins and peptides".InvestorsIn November 2012, Intarcia received $210M in preferred stock and debt financing from, The Baupost Group, Farallon Capital Management, New Enterprise Associates, New Leaf Venture Partners and Venrock Associates. [3] Other Investors include Greenspring Associates ,[4] Alta Partners and Granite Venture Partners. In April 2014, Intarcia secured an additional $200M in financing. RA Capital led the round and was joined by new and existing investors.[1] In April 2015, the company raised $225M in exchange for 1.5% of future global net sales of ITCA 650.[5] In May 2016, Intarcia secured an additional $75M in financing to scale-up manufacturing and inventory in anticipation of ITCA 650s global launch.[6] In September 2016, Intarcia raised an additional $215M in equity financing to prepare for the commercial launch of ITCA 650 in late 2017 and additional pipeline programs.[7] Notes1. ^1 {{cite web|url=http://www.fiercebiotech.com/r-d/investors-pump-200m-into-intarcia-s-phiii-for-once-yearly-diabetes-therapy|title=Investors pump $200M into Intarcia's PhIII for once-yearly diabetes therapy|website=www.fiercebiotech.com}}
2. ^{{cite web|url=https://www.bloomberg.com/markets/stocks|title=Stocks|website=Bloomberg.com}}
3. ^{{cite web | url=http://www.techrockies.com/story/0009464.html | date=November 15, 2012 | title=AtTaIntarcia raises $210M as it pushes once-a-year diabetes treatment into Phase III, moves HQ to Boston area | work=BizJournals | accessdate=November 7, 2013}}
4. ^{{cite web| url=http://greenspringassociates.com/direct-investments | date=November 7, 2013 | title=Direct Investments | work=Greenspring Associates | accessdate=November 7, 2013}}
5. ^{{cite web|url=https://www.wsj.com/articles/startup-intarcia-raises-225-million-1430186581|title=Startup Intarcia Raises $225 Million|first=Ron|last=Winslow|date=April 28, 2015|publisher=|via=www.wsj.com}}
6. ^{{cite web|url=http://www.fiercebiotech.com/medical-devices/intarcia-raises-75m-touts-final-data-as-it-preps-to-launch-once-yearly-diabetes|title=Intarcia raises $75M, touts final data as it preps to launch once-yearly diabetes drug implant|website=www.fiercebiotech.com}}
7. ^{{cite web|url=http://fortune.com/2016/09/15/diabetes-unicorn-raises-final-vc-round-before-ipo/|title=Diabetes 'Unicorn' Raises Final VC Round Before IPO|website=Fortune}}
8. ^1 {{Citation |publication-date=May 1, 2012 |title=Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus |work=ClinicalTrials.gov |url=http://www.clinicaltrials.gov/ct2/show/NCT00943917 |accessdate=November 15, 2012 }}
9. ^1 {{Citation |title=Exhibit 4.1 |publisher=SEC |url=https://www.sec.gov/Archives/edgar/data/1086688/000104746905022425/a2162566zex-4_1.htm |accessdate=November 15, 2012 }}
10. ^1 {{Citation |author=Ron Leuty |publication-date=November 15, 2012 |title=Intarcia raises $210M as it pushes once-a-year diabetes treatment into Phase III, moves HQ to Boston area |periodical=San Francisco Business Times |url=http://www.bizjournals.com/sanfrancisco/blog/biotech/2012/11/intarcia-diabetes-boston-fundraising.html |accessdate=November 15, 2012 }}
11. ^1 {{Citation |publication-date=March 18, 2005 |title=INTARCIA THERAPEUTICS, INC. |work=AMENDMENT NO. 1 TO FORM S-1 |edition= |series= |volume= |issue= |publisher=SEC |url=https://www.sec.gov/Archives/edgar/data/1086688/000104746905007071/a2153238zs-1a.htm |accessdate=November 15, 2012 }}
}}External links{{med-company-stub}}{{US-company-stub}} 4 : 1995 establishments in California|Health care companies based in Massachusetts|Pharmaceutical companies of the United States|Companies based in Boston |